Provided by Tiger Trade Technology Pte. Ltd.

Dare Bioscience

0.7301
-0.0062-0.84%
Post-market: 0.7300-0.0001-0.01%18:33 EDT
Volume:109.23K
Turnover:80.59K
Market Cap:14.36M
PE:-0.94
High:0.7713
Open:0.7413
Low:0.7200
Close:0.7363
52wk High:3.78
52wk Low:0.6900
Shares:19.67M
Float Shares:17.33M
Volume Ratio:0.55
T/O Rate:0.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7779
EPS(LYR):-1.1986
ROE:-2543.13%
ROA:-39.29%
PB:-25.60
PE(LYR):-0.61

Loading ...

DarÉ Bioscience Announces the Upcoming Launch of Flora Sync Lf5™ Vaginal Probiotic Capsules

THOMSON REUTERS
·
Jun 04

Daré Bioscience wins $1 million NIH grant tranche for DARE-HPV program

Reuters
·
May 26

Press Release: Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dow Jones
·
May 26

BRIEF-Daré Bioscience Initiates Phase 2 Study Of Dare-Hpv

Reuters
·
May 18

Daré Bioscience starts Phase 2 trial of DARE-HPV vaginal insert for high-risk HPV infection

Reuters
·
May 18

DarÉ Bioscience Initiates Phase 2 Study of Dare-Hpv, a Novel Pharmacologic Treatment for Persistent High-Risk Hpv Infection With No FDA-Approved Therapies

THOMSON REUTERS
·
May 18

Dare Bioscience Inc - Dare-Hpv Development Supported by $10 Mln Arpa-H Contract; Topline Data Expected in 2027

THOMSON REUTERS
·
May 18

Dare Bioscience Inc - Phase 2 Study to Enroll About 100 Women Over up to 21 Days

THOMSON REUTERS
·
May 18

Dare Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 15

BRIEF-Daré Bioscience Reports First Quarter 2026 Financial Results

Reuters
·
May 15

Dare Bioscience Q1 FY26 net loss narrows 31% to $3 million

Reuters
·
May 15

Dare Bioscience Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $152.455K Miss $984.667K Estimate

Benzinga Earnings
·
May 15

Dare Bioscience, Inc. Q1 EPS USD -0.2

THOMSON REUTERS
·
May 15

Corrected-Dare Bioscience, Inc. Q1 Net Income USD -3 Million (Corrects Amount)

THOMSON REUTERS
·
May 15

Dare Bioscience Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
May 13

Dare Bioscience reports positive interim Phase 3 results for Ovaprene

TIPRANKS
·
May 13

Daré Bioscience reports positive interim Phase 3 data for hormone-free contraceptive Ovaprene

Reuters
·
May 12

Dare Bioscience Inc - 12% of Participants Discontinued Study Due to Vaginal Odor, Down 5% From July 2025

THOMSON REUTERS
·
May 12

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

THOMSON REUTERS
·
May 12

Dare Bioscience Inc - No Serious Adverse Events Related to Ovaprene Device Identified

THOMSON REUTERS
·
May 12